Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Artemether/lumefantrine - Novartis

Next Previous
Drug Profile

Artemether/lumefantrine - Novartis

Alternative Names: Benflumetol; CGP 56697; Co-artemether; COA566; Coartem; Coartem Dispersible; Exafal; Lumefantrine/artemether; Riamet

Latest Information Update: 11 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Academy of Military Medical Sciences (Beijing)
  • Developer Medicines for Malaria Venture; Novartis
  • Class Anthelmintics; Antifungals; Antimalarials; Antiprotozoals; Artemisinins; Ethanolamines; Fluorenes; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Carrier protein inhibitors; Hemozoin inhibitors; Mitochondrial protein inhibitors; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malaria
  • New Molecular Entity No

Highest Development Phases

  • Marketed Malaria

Most Recent Events

  • 08 Jul 2025 Registered for Malaria (In infants, In neonates) in Switzerland (PO)
  • 25 Apr 2024 Interim pharmacokinetics data from a phase II/III CALINA trial on malaria released by Novartis
  • 31 Mar 2024 Preregistration for Malaria (In neonates, In infants) in Switzerland (PO), before March 2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top